Physician profile
Kenneth Ewane
NPI 1992056048
$9,854.18
in general payments reported to CMS, 2019-2025
27 companies · $227 in 2025
The $227 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,498 · 2020: $205 · 2021: $416 · 2022: $473 · 2023: $2,143 · 2024: $1,894 · 2025: $227.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $3,070 · Food and Beverage: $1,193.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $3,069.94 |
| Food and Beverage | $1,193.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $4,178.02 | 2019-2025 | Rezum Generator, Ams 700, Axonics |
| Intuitive Surgical, INC. | $1,992.83 | 2021-2024 | |
| Medtronic, INC. | $1,701.61 | 2023 | Interstim, Stealthstation S8 Platform |
| Astellas Pharma US INC | $455.93 | 2019-2025 | Myrbetriq, Xtandi, Veozah |
| Coloplast Corp | $224.02 | 2021-2024 | Titan |
| Merck Sharp & Dohme LLC | $181.59 | 2022-2025 | Keytruda, Lynparza, Welireg |
| Sumitomo Pharma America, INC. | $151.98 | 2023-2024 | Gemtesa, Orgovyx |
| Allergan, INC. | $126.61 | 2019-2020 | |
| Abbvie INC. | $123.34 | 2019-2022 | |
| Janssen Biotech, INC. | $86.18 | 2020-2025 | Erleada |
| Bayer Healthcare Pharmaceuticals INC. | $70.00 | 2022-2025 | |
| Axonics, INC. | $63.96 | 2022-2024 | Bulkamid, Axonics |
| Zyla Life Sciences, INC. | $52.28 | 2019-2020 | |
| Procept Biorobotics Corporation | $51.95 | 2022 | |
| Urovant Sciences INC | $47.42 | 2021-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endo Pharmaceuticals INC. | $45.06 | 2019-2021 | |
| Pfizer INC. | $40.32 | 2019-2020 | |
| Myriad Genetic Laboratories, INC. | $35.60 | 2024-2025 | Prolaris |
| Ethicon US, LLC | $35.00 | 2021 | |
| Aytu Biopharma, INC. | $33.10 | 2019 | |
| C. R. Bard, INC. & Subsidiaries | $32.06 | 2023-2025 | |
| Myovant Sciences INC. | $22.63 | 2022 | |
| 180 Medical, INC. | $22.07 | 2024 | |
| Teleflex LLC | $21.24 | 2024 | Urolift |
| Ferring Pharmaceuticals INC. | $20.95 | 2025 | Adstiladrin |
| Tolmar, INC. | $19.68 | 2025 | Jatenzo, Eligard |
| Antares Pharma, INC. | $18.75 | 2023 | Tlando, Xyosted, Nocdurna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Ewane listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.